←
Tom Powles2,780 posts
Tom Powles avatar✓

Tom Powles ✓

@tompowles1

Interested in Urology Cancers, biomarkers and drug development.

◷ Joined December 2019▧ 808 Photos and videos
OncoAlert avatar
⟳ Tom Powles retweeted
OncoAlert@OncoAlert·Nov 16

The OncoAlert 🚨 Coverage of #UromigosLIVE 🎸 2026 ctDNA: can we spare adjuvant EV? Dr. Jonathan Rosenberg 🇺🇸 @DrRosenbergMSK of @MSKCancerCenter discusses with Dr. Michiel van der Heijden🇳🇱 @MichvdHeijden of @NKI_nl on how he uses ctDNA in MIBC today: 🔹 Mostly post-op, based on IMvigor011: it helps risk-stratify patients, especially after an excellent pathologic response to neoadjuvant therapy 🔹 Rising ctDNA before surgery is a very bad sign. Consider other approaches before cystectomy 🔹 Clear before surgery, negative after and staying negative: these patients do really, really well 🔹 Bladder preservation cuts both ways. Persistently positive patients likely fail distantly, but some clear their ctDNA with surgery. Would they also clear with chemoradiation or more EV-P? EV-209, EV-309 and sac-TMT + pembro trials should help answer this 🔹 ctDNA down but not cleared → go to surgery, then continue adjuvant therapy 💬 "Surgery is curing patients. It's just not curing all patients." 💡 After VOLGA, he's more likely to drop adjuvant EV: great neoadjuvant response + ctDNA-negative after surgery → most are probably cured. Less EV means less toxicity, and some of it is long-term. Would you de-escalate adjuvant EV based on ctDNA? 👇 #BladderCancer #MIBC #ctDNA #GUOnc @Uromigos, @tompowles1, @brian_rini, @shilpaonc, @montypal, @TiansterZhang, @neerajaiims, @katy_beckermann, @PGrivasMDPhD, @TwoOncDocs, @DrKarineTawagi, @nataliagandur, @Dr_Aggen, @AmandaNizamMD, @scocmem, @lalaniMD, @NazliDizman, @weoncologists, @LosUromigos, @uromigosjapan

5:17
Uromigos avatar
⟳ Tom Powles retweeted
Uromigos@Uromigos·Nov 16

EV + pembrolizumab vs. EV + durvalumab. How does the VOLGA trial impact treatment decisions in muscle-invasive bladder cancer? Listen to the full debate, recorded live at #UromigosLive in Nashville 🎸 🎧 Spotify: bit.ly/4kkdcQc 🎧 Apply: apple.co/48Gvvbn

Post attachment
Yao Zhu avatar
⟳ Tom Powles retweeted
Yao Zhu@yao_zhu_sh·Nov 15

Back home with inspiration and new ideas. Thanks again to @tompowles1 and @brian_rini for hosting such a great brainstorming meeting—and our team really enjoyed the #UromigosLive World Cup. With 3 pages of UC trials in CN, we have more to do to provide better care globally.

Post attachmentPost attachmentPost attachmentPost attachment
Tom Powles avatar
Tom Powles@tompowles1·Nov 15

Ivonescimab (with chemo) has been rejected by FDA in EGFRm TKI refractory lung cancer. The trial achieved impressive PFS but not OS (with some subgroup inconsistency). We see PFS achieve approvals without OS in other tumours including all 3 GU cancers. It’s not always easy to predict the future in terms of results or regulatory approvals, but the class of drug seems broadly active. VEFF/PD1s are in R3 trials in bladder cancer with EV. @OncoAlert google.com/goto?url=CAESwgEB…

Uromigos avatar
⟳ Tom Powles retweeted
Uromigos@Uromigos·Nov 15

And in the end Belgium wins #uromigosLive @OncoAlert 🇧🇪 Belgium 🇧🇪 Belgium 🇧🇪 Belgium 🇧🇪 🏆 🏆. 🏆 🏆 m (with a little help from France 🇫🇷 )

Post attachment
3:29
Amanda Nizam, MD avatar
⟳ Tom Powles retweeted
Amanda Nizam, MD@AmandaNizamMD·Nov 14

Discussion of @BethN01’s eloquent ASCO 2026 presentation on redefining toxicity assessments in oncology. CTCAE doesn’t capture the whole story. Cumulative incidence & point prevalence of TRAEs needed to better capture chronic toxicity burden over time. More granular toxicity data including time to onset, severity, duration, resolution rate, time to resolution, and PROs would improve Tx counseling. #UromigosLIVE @Uromigos @LosUromigos @tompowles1 @scocmem @BlancJeremy @brian_rini @OncoAlert @crisbergerot @niklas_kluemper

Post attachment
OncoAlert avatar
⟳ Tom Powles retweeted
OncoAlert@OncoAlert·Nov 14

OncoAlert🎙️ Live from Broadway, Nashville at #UromigosLIVE 2026 @tompowles1 🇬🇧 & @brian_rini 🇺🇸break down PROTEUS 🔹 Main trial (ASCO plenary): apalutamide + ADT around radical prostatectomy improved MFS. But the control arm already used ADT, and most events were found on PSMA PET 🔹 Sub-study (ESMO, ~400 pts): same experimental arm vs surgery alone. The curves separate even more, but follow-up is shorter ❓ Is it just proof that hormone therapy works, or practice-changing? Is MFS enough without OS? #ProstateCancer @Uromigos, @tompowles1, @brian_rini, @shilpaonc, @montypal, @TiansterZhang, @neerajaiims, @katy_beckermann, @PGrivasMDPhD, @TwoOncDocs, @DrKarineTawagi, @nataliagandur, @Dr_Aggen, @AmandaNizamMD, @scocmem, @lalaniMD, @NazliDizman, @weoncologists, @LosUromigos, @uromigosjapan

3:24
Sumanta K. Pal, MD, FASCO avatar
⟳ Tom Powles retweeted
Sumanta K. Pal, MD, FASCO@montypal·Nov 14

One of the coolest sessions at #UromigoLive - clinical trial proposals from rising stars! Glad to be paired with @lalaniMD who crafted a really clever prospective trial assessing pts w low #KIM1, randomizing to pembro v surveillance. Using a novel WIN Ratio is a means of getting some preliminary evidence. See the photo of him below, dominating the stage both literally & figuratively! Great job Aly Khan! @tompowles1 @brian_rini @OncoAlert

Post attachmentPost attachmentPost attachmentPost attachment